NumFin

Nuo Therapeutics, Inc.

Symbol: AURX

PNK

0.8

USD

Market price today

  • -10.7721

    P/E Ratio

  • -0.1077

    PEG Ratio

  • 35.39M

    MRK Cap

  • 0.00%

    DIV Yield

Nuo Therapeutics, Inc. (AURX) Financial Statements

Download
AnnualQuarterly
LinearLog
On the chart you can see the default numbers in dynamics for Nuo Therapeutics, Inc. (AURX). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

AnnualQuarterly
10Y20Y30Y40Y

Balance Sheet

Diving into the fiscal trajectory of Nuo Therapeutics, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999

balance-sheet.row.cash-and-short-term-investments

00.92.10.1
0.2
0.2
0.6
0.7
2.7
1
15.9
3.3
2.7
2.3
0.7
2.2
4
5.1
4.7
3.1
3.3
0.8
0.9
0.2
2.1
0.1

balance-sheet.row.short-term-investments

0000
0
0.2
0
0
0
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

00.30.10
0
0
0
0.1
0.7
1
1.9
3.9
1.7
1.5
1.2
0.2
0.5
0.7
1
0.4
0.3
0.2
0.2
0
0.2
0

balance-sheet.row.inventory

00.20.20
0
0
0
0
0.1
0.3
0.6
1.1
1.2
0.5
0.6
166731
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

00.20.20
0
0
0.2
0.3
0.3
0.8
2.3
0
0.1
0.8
1
0.2
0
0.1
0
0
0.3
0.2
0.3
0.3
0.1
0

balance-sheet.row.total-current-assets

01.62.60.1
0.2
0.2
0.9
1.2
3.8
3
21.9
10
6.4
5.2
3.5
2.5
4.7
6.1
5.8
3.8
3.9
1.2
1.4
0.5
2.5
0.2

balance-sheet.row.property-plant-equipment-net

00.30.40
0
0
0.1
0.2
0.5
1.1
0.9
0.9
2.4
1
1.3
0.1
0.1
0
0
0.1
0.2
0.2
0.3
0
0.5
0.1

balance-sheet.row.goodwill

0000
0
0
0
0
2.1
0
1.1
1.1
1.1
0.7
0.7
0
0
2
2
2
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
7.8
2.5
28.7
33.8
34.1
2.9
3.2
0
0
1.7
1.8
2
4.1
4.2
4.4
0.6
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
9.9
2.5
29.9
34.9
35.3
3.6
3.9
0
0
3.7
3.8
4
4.1
4.2
4.4
0.6
0
0

balance-sheet.row.long-term-investments

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0000
0
0
0
0
0.3
0.4
3.5
0.5
0.2
0.3
0.2
0
0
0.2
0.6
0
0
0
0
0.1
0.9
0

balance-sheet.row.total-non-current-assets

00.30.40
0
0
0.1
0.2
10.7
4
34.3
36.3
37.9
4.9
5.4
0.1
0.1
3.9
4.4
4.1
4.3
4.5
4.7
0.7
1.4
0.1

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

01.930.1
0.2
0.2
1
1.4
14.5
7.1
56.2
46.3
44.3
10.1
8.9
2.6
4.8
10
10.2
7.9
8.2
5.7
6.2
1.2
3.9
0.3

balance-sheet.row.account-payables

00.40.40.5
0.5
0.5
0.4
0.4
0.4
1.1
1.9
3.4
1.4
1.2
3.6
1
1.3
0.1
1.2
1.1
1
0.6
0.7
0.1
0.8
0.1

balance-sheet.row.short-term-debt

00.10.10
0
0.7
0.3
0
-0.1
35
2.5
1.8
0
0
1.5
0
0
0.8
0
0
0
0
0
0.2
0
0.2

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

00.20.30
0
0
0
0
0
0
0.3
3.8
2.1
2.1
2
0
0
0
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

0000
0
0
0
0
0
0.6
1
1.4
-0.7
0
0
0
0
197344
191475
263745
0
0
0
0.6
0
0.1

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

00.30.10.1
0.1
0.1
0.3
0.5
1
5
3.7
2.9
1.4
1.3
0.1
0
0
0
0
0
0.2
0.1
0
0.1
-0.1
0

balance-sheet.row.total-non-current-liabilities

00.20.30
0
0
0.7
0
0.2
1.4
31.8
9.4
3.5
3.7
3.8
1
0.1
0.2
0.4
0.3
0.4
0.4
0.6
10
1.8
1.7

balance-sheet.row.other-liabilities

0000
0
0
-0.7
0
0
0
0
0
0
0
0
-1
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

00.20.30
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

00.80.90.7
0.7
0.7
1.1
0.9
1.6
43.6
40.3
19.9
6.3
6.8
9
1
1.7
1.4
1.7
1.5
1.7
1.3
1.5
10.8
2.9
2.1

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

0000
0
0
0
0
0
0
0.9
0.4
0.5
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

0-29.9-26.8-23.5
-23.5
-23.5
-22.2
-20.7
-5.2
-162.9
-110.1
-91.2
-71
-51.2
-47.7
-42.5
-39.1
-31.4
-26.6
-24.3
-17.7
-6.5
-2.1
-60.8
-39.6
-6.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

0000
0
0
0
0
-0.1
0
0
0
0
0
0
0
0
0
-0.6
-0.2
-1.4
-1.4
-0.2
0
0
0

balance-sheet.row.other-total-stockholders-equity

0312923
23
23
22.1
21.2
18.2
126.3
125.2
117.1
108.5
54.5
47.6
44.1
42.2
40
35.8
31
25.7
12.4
6.9
51.3
40.6
4.4

balance-sheet.row.total-stockholders-equity

012.2-0.5
-0.5
-0.5
-0.1
0.5
12.9
-36.6
16
26.3
38
3.3
-0.1
1.5
3.1
8.6
8.5
6.4
6.5
4.5
4.7
-9.6
1
-1.8

balance-sheet.row.total-liabilities-and-stockholders-equity

01.930.1
0.2
0.2
1
1.4
14.5
7.1
56.2
46.3
44.3
10.1
8.9
2.6
4.8
10
10.2
7.9
8.2
5.7
6.2
1.2
3.9
0.3

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

012.2-0.5
-0.5
-0.5
-0.1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

0000
0
0.2
0
0
0
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-debt

00.30.30
0
0.7
0.3
0
0
35
0.3
5.6
2.1
2.1
3.5
0
0
0
0
0
0
0
0
0.2
0
0.2

balance-sheet.row.net-debt

0-0.7-1.7-0.1
-0.2
0.5
-0.3
-0.7
-2.7
34.1
-15.6
2.3
-0.5
-0.1
2.9
-2.1
-4
-5.1
-4.7
-3.1
-3.3
-0.8
-0.9
0
-2.1
0.1

Cash Flow Statement

The financial landscape of Nuo Therapeutics, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999

cash-flows.row.net-income

0-3.2-3.20
0
0
-1.5
-15
0
-52.8
-18.9
-20.2
-19.8
-3.5
-6.8
-3.4
-7.7
-5
-2.3
-6.5
-8.1
-4.1
-2
-21.2
-33.3
-6.2

cash-flows.row.depreciation-and-amortization

00.10.10
0
0.1
0.1
1.1
0
0.7
0.6
1.1
1.2
0.6
0.4
0
0.2
0.2
0.2
2.2
3.3
1.2
0.1
0.5
0.1
0

cash-flows.row.deferred-income-tax

0000
0
-0.4
-0.2
0
0
-0.1
0
0
0
0
0
-0.4
3.5
-1014966
-129794
-1526088
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

00013936
0.3
0.1
0
0.1
0
0.8
1.3
0.7
2
0.3
0.4
0.4
0.7
1014966
129794
1526088
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

0-0.3-0.50
0
0
0.7
-0.3
0
0.2
0.8
5.2
-1.5
-1.3
1.6
-0.3
0.8
0.4
-0.8
-0.1
0.1
0.1
-0.6
0.5
0.4
0.1

cash-flows.row.account-receivables

0-0.3-0.10
0
0
0.3
277.1
0
695612
2005581
-2268104
-260510
-0.9
-1
0.3
0.2
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

00-0.20
0
0
0
0
0
0.3
0.5
0.1
-0.6
0.1
0.5
287430.7
-377027.4
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

0000
0
0
0.1
0
0
-0.8
-1.5
5206301
-83767
-1055983
2356062
-287431
377028
-190818
98217
94678
0
0
0
0
0
0

cash-flows.row.other-working-capital

00-0.20
0
0
0.4
-277.4
0
-695611.2
-2005579.2
-2938191.9
344276.1
1055982.5
-2356059.9
-0.3
-0.1
190818.4
-98217.8
-94678.1
0.1
0.1
-0.6
0.5
0.4
0

cash-flows.row.other-non-cash-items

00.2-0.1-13936
-0.3
-0.1
0
9.2
0
36.7
-1.2
1.9
6.7
-0.3
0.8
0.4
0
2.3
1.2
0.2
0
0.1
0.5
17.4
28.3
5.4

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

00-0.10
0
0
0
0
0
-0.7
-0.5
-0.8
-2.1
-0.1
-0.8
0
-0.1
0
0
0
-0.1
0
-0.3
0
-0.6
0

cash-flows.row.acquisitions-net

0000
0
0
0
0
0
0
0
0
0
0
-2
0
0
0
0
0
0
0
0
-2.4
0
0

cash-flows.row.purchases-of-investments

0000
0
0
0
0
0
0
0
0
0
0
0
-0.1
0
0
0
0
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

0000
0
0
0
0.1
0
0.1
0.1
2.1
0.5
0.1
0.1
0
0
0
0
0.1
0
0
0
0.2
-0.8
0.4

cash-flows.row.net-cash-used-for-investing-activites

00-0.10
0
0
0
0.1
0
-0.6
-0.3
1.4
-1.6
0
-2.7
-0.1
-0.1
0
0
0.1
-0.1
0
-0.3
-2.3
-1.4
0.4

cash-flows.row.debt-repayment

0000
0
0
0
0
0
0
-6.2
-1
-9.5
-2.6
-0.5
0
0
0
-11035
0
0
0
0
0
-0.2
-0.2

cash-flows.row.common-stock-issued

024.51.4
0.2
0
0.5
2.9
0
0
3.7
5.5
9.5
3.8
1.9
1.4
1.4
2.6
3.2
4
7.2
2.7
3.2
0
8
0.4

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
-0.2
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-11035
-0.1
0
0
0
0
0
0

cash-flows.row.other-financing-activites

024.51373092
0.2
0.3
0.3
0
0
0
33
6.2
13.6
4.7
3.4
0
0
0
22070
0
0
-0.1
-0.1
3.2
0
0.2

cash-flows.row.net-cash-used-provided-by-financing-activities

024.51373092
0.2
0.3
0.8
2.9
0
0
30.4
10.7
13.4
5.8
4.8
1.4
1.4
2.6
3.2
3.9
7.2
2.6
3.1
3.2
7.8
0.4

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

0-1.20.70
0
0
-0.1
-1.9
0
-15
12.7
0.7
0.4
1.6
-1.5
-1.9
-1.1
0.5
1.5
-0.2
2.5
-0.1
0.9
-1.9
2
0.1

cash-flows.row.cash-at-end-of-period

00.92.10.1
0.2
0.2
0.6
0.7
0
0.9
15.9
3.3
2.6
2.2
0.6
2.1
4
5.1
4.7
3.1
3.3
0.8
1
0.2
2.1
0.1

cash-flows.row.cash-at-beginning-of-period

02.11.40.2
0.2
0.2
0.7
2.6
0
15.9
3.3
2.6
2.2
0.6
2.1
4
5.1
4.7
3.1
3.3
0.8
0.9
0.1
2.1
0.1
0

cash-flows.row.operating-cash-flow

0-3.2-3.70
0
0
-0.9
-4.9
0
-14.4
-17.4
-11.4
-11.4
-4.2
-3.5
-3.2
-2.5
-2.1
-1.7
-4.2
-4.7
-2.7
-1.9
-2.8
-4.4
-0.7

cash-flows.row.capital-expenditure

00-0.10
0
0
0
0
0
-0.7
-0.5
-0.8
-2.1
-0.1
-0.8
0
-0.1
0
0
0
-0.1
0
-0.3
0
-0.6
0

cash-flows.row.free-cash-flow

0-3.2-3.80
0
0
-0.9
-4.9
0
-15.1
-17.9
-12.2
-13.5
-4.3
-4.3
-3.3
-2.6
-2.2
-1.7
-4.2
-4.8
-2.7
-2.2
-2.9
-5
-0.7

Income Statement Row

Nuo Therapeutics, Inc.'s revenue saw a change of NaN% compared with the previous period. The gross profit of AURX is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999

income-statement-row.row.total-revenue

00.60.10
0
0.1
1.4
0.7
2205
11.5
7.8
11.6
10.6
7.2
3.9
2.1
2.1
1.9
1.9
1.5
1.1
1.1
0.4
0
0.3
0

income-statement-row.row.cost-of-revenue

00.100
0
0.1
0.2
1.1
1613
8
6.8
8.5
3.9
2.7
1.6
0.5
0.6
0.9
1
0.9
0.7
0.8
0.1
0
0.1
0

income-statement-row.row.gross-profit

00.50.10
0
0
1.2
-0.4
592
3.5
1
3.1
6.6
4.5
2.3
1.6
1.5
1.1
0.9
0.6
0.4
0.3
0.3
0
0.3
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0000
0
0
0
0.6
0
0
0
0
-2
1473670
1930655
2187696
6018366
1028137
1528361
4706508
0
0
0.4
3.7
31.9
3.2

income-statement-row.row.operating-expenses

03.73.40.1
0.4
1
2.7
5.9
0
17.8
19.7
21.2
19.5
8
7.7
5.1
5.8
6.4
5.1
8.1
8.6
4.5
2.4
5.5
33.7
3.5

income-statement-row.row.cost-and-expenses

03.83.40.1
0.4
1.1
2.9
7
1613
25.8
26.5
29.7
23.5
10.8
9.3
5.5
6.4
7.3
6.1
9
9.3
5.2
2.4
5.5
33.8
3.5

income-statement-row.row.interest-income

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0.3
0.2
0.1
0.1
0
0
0
0.2
0

income-statement-row.row.interest-expense

000-48390
0
0.2
0
0
0
3.8
3.4
1.7
1
1
-0.8
0
0.2
-0.3
-1.9
-6.5
0
0
0
5.6
0
-6.2

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

000.1287189
0.3
-0.2
0
-8.7
0
-34.9
3.3
-0.5
-5.8
1.1
-0.6
0
-3.5
0
1.7
0.8
0
0
-0.3
11.1
-0.4
-2.7

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0000
0
0
0
0.6
0
0
0
0
-2
1473670
1930655
2187696
6018366
1028137
1528361
4706508
0
0
0.4
3.7
31.9
3.2

income-statement-row.row.total-operating-expenses

000.1287189
0.3
-0.2
0
-8.7
0
-34.9
3.3
-0.5
-5.8
1.1
-0.6
0
-3.5
0
1.7
0.8
0
0
-0.3
11.1
-0.4
-2.7

income-statement-row.row.interest-expense

000-48390
0
0.2
0
0
0
3.8
3.4
1.7
1
1
-0.8
0
0.2
-0.3
-1.9
-6.5
0
0
0
5.6
0
-6.2

income-statement-row.row.depreciation-and-amortization

00.10.10.1
0.1
0
0.1
1.1
0
0.7
0.6
1.1
1.2
0.6
0.4
0
0.2
0.2
0.2
2.2
3.3
1.2
0.1
0.5
0.1
0

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

0-3.2-3.3-0.1
-0.4
-1
-1.5
-15.5
592
-41.3
-23.4
-18.1
-12.9
-3.5
-5.4
-3.4
-7.9
-5.4
-4.2
-7.4
-8.2
-4.1
-2
-5.4
-33.5
-6.2

income-statement-row.row.income-before-tax

0-3.2-3.2-0.1
-0.1
-1.2
-1.5
-15
0
-52.9
-18.9
-20.2
-19.8
-3.5
-6.8
-3.4
-7.7
-5
-2.3
-6.5
-8.1
-4.1
-2
-21.2
-33.3
-6.2

income-statement-row.row.income-tax-expense

00-0.1287188.9
0
0.2
0
-0.6
0
-0.1
0
0
0
0
0
0
-0.2
-0.3
-1.9
6.5
8.1
4.1
2
21.2
33.3
6.2

income-statement-row.row.net-income

0-3.2-3-0.1
-0.1
-1.4
-1.5
-15
0
-52.8
-18.9
-20.2
-19.8
-3.5
-6.8
-3.4
-7.7
-5
-2.3
-6.5
-8.1
-4.1
-2
-21.2
-33.3
-6.2
Similar Stocks
You may also be interested in:
MRVI
Maravai LifeSciences Holdings, Inc..
9.86 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.02684 USD
NASDAQ
GUBRA.CO
Gubra A/S.
338 DKK
CPH
T5O.DE
CytoTools AG.
0.406 EUR
XETRA
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ
SPHRF
Starpharma Holdings Limited.
0.0774 USD
PNK

Frequently Asked Question

What is Nuo Therapeutics, Inc. (AURX) total assets?

Nuo Therapeutics, Inc. (AURX) total assets is 1877880.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 0.793.

What is company free cash flow?

The free cash flow is -0.074.

What is enterprise net profit margin?

The net profit margin is -5.214.

What is firm total revenue?

The total revenue is -5.206.

What is Nuo Therapeutics, Inc. (AURX) net profit (net income)?

The net profit (net income) is -3171436.000.

What is firm total debt?

The total debt is 255592.000.

What is operating expences number?

The operating expences are 3650707.000.

What is company cash figure?

Enretprise cash is 0.000.